CGEM - Cullinan Therapeutics Announces Positive End-of- Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrat
CGEM - Cullinan Therapeutics Announces Positive End-of- Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML
Story updates
11:14:06 AM UTC
SquawkNews
Cullinan Therapeutics announces End-of-Phase 1 meeting for CLN-049 with FDA
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.